{"id":249820,"date":"2023-08-10T00:00:00","date_gmt":"2023-08-10T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfim0004-2023-biopharma-sjogrens-syndrome-landscape-forecast\/"},"modified":"2026-03-31T10:32:25","modified_gmt":"2026-03-31T10:32:25","slug":"nrlfim0004-2023-biopharma-sjogrens-syndrome-landscape-forecast-disease-landscape-forecast","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/nrlfim0004-2023-biopharma-sjogrens-syndrome-landscape-forecast-disease-landscape-forecast\/","title":{"rendered":"Sjogren&#8217;s Syndrome &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast"},"content":{"rendered":"<p>Sj\u00f6gren\u2019s syndrome (<abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>) is a progressive autoimmune disease characterized by chronic inflammation and lymphocytic infiltration of the exocrine glands; the disease may occur alone (primary <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>) or with a comorbid autoimmune condition (secondary <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>). Symptomatic therapies to treat dry eyes, dry mouth, and\/or specific extraglandular manifestations are the cornerstone of disease management. Systemic manifestations are most often treated with hydroxychloroquine or, in severe cases, systemic immunomodulators (e.g., azathioprine, methotrexate). Therapies with disease-modifying potential are in development for <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> (e.g., Novartis\u2019s iscalimab and ianalumab and\u00a0Horizon Therapeutic\u2019s dazodalibep), targeting key pathways believed to drive pathological processes in the disease. These putative disease-modifying therapies have the potential to transform the management of <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr>, although SS is an indication in which such success has historically been a challenge.<\/p>\n<p><strong>Questions answered <\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>How large is the <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> population and how will its size change over time?<\/li>\n<li>How is <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> currently managed? What are the current treatments, and what drives their use?<\/li>\n<li>Which unfulfilled clinical needs are the most pressing?<\/li>\n<li>Which pipeline products are the most promising, and what sales might they garner in the <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> market? What therapies of note are progressing in earlier phases?<\/li>\n<li>What clinical roles will Novartis\u2019s iscalimab and ianalumab, and Horizon Therapeutics\u2019 dazodalibep play in the evolving <abbr data-abbreviation-entity=\"6491\" title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> treatment landscape?<\/li>\n<li>What are the drivers of and constraints in the <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> market, and how will the market evolve through 2032?<\/li>\n<\/ul>\n<p><strong>Content highlights <\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Geographies: United States and <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>.<\/li>\n<li>Primary research: Six country-specific interviews with thought-leading <abbr data-abbreviation-entity=\"6491\" title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> specialists supported by survey data collected for this study.<\/li>\n<li>Epidemiology: Diagnosed and drug-treated prevalent cases of <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> by country, diagnosed prevalence by subtype.<\/li>\n<li>Forecast: Drug-level sales and patient share of key <abbr title=\"Sj\u00f6gren\u2019s syndrome\">SS<\/abbr> therapies through 2032.<\/li>\n<li>Emerging therapies: Phase 3\/PR: 1 drug;\u00a0Phase 2: 7+ drugs; coverage of select early-phase products.<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Niche &#038; Rare Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution enhancement<\/strong><\/p>\n<p>Niche &#038; Rare Disease Landscape &#038; Forecast introduces a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-249820","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatology","biopharma-therapy-areas-sjogrens-syndrome","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249820","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249820\/revisions"}],"predecessor-version":[{"id":576080,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249820\/revisions\/576080"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249820"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}